Literature DB >> 18945331

Pathophysiology and management of fluid and electrolyte disturbances in patients on chronic dialysis with severe hyperglycemia.

Antonios H Tzamaloukas1, Todd S Ing, Kostas C Siamopoulos, Dominic S C Raj, Moses S Elisaf, Mark Rohrscheib, Glen H Murata.   

Abstract

The mechanisms of fluid and solute abnormalities that should be considered in any patient with severe hyperglycemia include changes in the total amount of extracellular solute, osmotic diuresis, intake of water driven by thirst, and influences from associated conditions. The absence of osmotic diuresis distinguishes dialysis-associated hyperglycemia (DH) from hyperglycemia with preserved renal function (HPRF). Mainly because of this absence, comparable degrees of hyperglycemia tend to produce less hypertonicity and less severe intracellular volume contraction in DH than in HPRF, while extracellular volume is expanded in DH but contracted in HPRF. Ketoacidosis can develop in both DH and HPRF. Among DH patients, hyperkalemia appears to be more frequent when ketoacidosis is present than when nonketotic hyperglycemia is present. Among HPRF patients, the frequency of hyperkalemia appears to be similar whether ketoacidosis or nonketotic hyperglycemia is present. Usually patients with severe DH have no symptoms or may exhibit a thirst. Infrequent clinical manifestations of DH include coma and seizures from hypertonicity or ketoacidosis and pulmonary edema from extracellular expansion. Insulin infusion is usually the only treatment required to correct the biochemical abnormalities and reverse the clinical manifestations of DH. Monitoring of the clinical manifestations and biochemical parameters during treatment of DH with insulin is needed to determine whether additional measures, such as administration of saline, free water, or potassium salts, as well as emergency hemodialysis (HD) are needed. Emergency HD carries the risk of excessively rapid decline in tonicity; its benefits in the treatment of DH have not been established.

Entities:  

Mesh:

Year:  2008        PMID: 18945331     DOI: 10.1111/j.1525-139X.2008.00464.x

Source DB:  PubMed          Journal:  Semin Dial        ISSN: 0894-0959            Impact factor:   3.455


  15 in total

Review 1.  Abnormalities of serum potassium concentration in dialysis-associated hyperglycemia and their correction with insulin: a unique clinical/physiologic exercise in internal potassium balance.

Authors:  Antonios H Tzamaloukas; Todd S Ing; Moses S Elisaf; Dominic S C Raj; Kostas C Siamopoulos; Mark Rohrscheib; Glen H Murata
Journal:  Int Urol Nephrol       Date:  2010-09-19       Impact factor: 2.370

2.  Volume depletion versus dehydration: how understanding the difference can guide therapy.

Authors:  Gautam Bhave; Eric G Neilson
Journal:  Am J Kidney Dis       Date:  2011-06-25       Impact factor: 8.860

3.  Mathematical analysis of circadian disruption and metabolic re-entrainment of hepatic gluconeogenesis: the intertwining entraining roles of light and feeding.

Authors:  Seul-A Bae; Ioannis P Androulakis
Journal:  Am J Physiol Endocrinol Metab       Date:  2018-01-09       Impact factor: 4.310

Review 4.  Abnormalities of serum potassium concentration in dialysis-associated hyperglycemia and their correction with insulin: review of published reports.

Authors:  Antonios H Tzamaloukas; Todd S Ing; Moses S Elisaf; Dominic S C Raj; Kostas C Siamopoulos; Mark Rohrscheib; Glen H Murata
Journal:  Int Urol Nephrol       Date:  2010-09-09       Impact factor: 2.370

Review 5.  Dialysis-associated hyperglycemia: manifestations and treatment.

Authors:  Yijuan Sun; Maria-Eleni Roumelioti; Kavitha Ganta; Robert H Glew; James Gibb; Darlene Vigil; Catherine Do; Karen S Servilla; Brent Wagner; Jonathan Owen; Mark Rohrscheib; Richard I Dorin; Glen H Murata; Antonios H Tzamaloukas
Journal:  Int Urol Nephrol       Date:  2020-01-18       Impact factor: 2.370

6.  Assessment of Selected Serum Electrolyte and Associated Risk Factors in Diabetic Patients.

Authors:  Shiferaw Bekele Woyesa; Waqtola Cheneke Gebisa; Delebo Lefebo Anshebo
Journal:  Diabetes Metab Syndr Obes       Date:  2019-12-31       Impact factor: 3.168

7.  Biochemical Parameters of Diabetes Ketoacidosis in Patients with End-stage Kidney Disease and Preserved Renal Function.

Authors:  Rodolfo J Galindo; Francisco J Pasquel; Priyathama Vellanki; Cesar Zambrano; Bonnie Albury; Citlalli Perez-Guzman; Zheng Ziduo; Guillermo E Umpierrez
Journal:  J Clin Endocrinol Metab       Date:  2021-06-16       Impact factor: 5.958

Review 8.  Glycemic Monitoring and Management in Advanced Chronic Kidney Disease.

Authors:  Rodolfo J Galindo; Roy W Beck; Maria F Scioscia; Guillermo E Umpierrez; Katherine R Tuttle
Journal:  Endocr Rev       Date:  2020-10-01       Impact factor: 19.871

Review 9.  Management of adult diabetic ketoacidosis.

Authors:  Aidar R Gosmanov; Elvira O Gosmanova; Erika Dillard-Cannon
Journal:  Diabetes Metab Syndr Obes       Date:  2014-06-30       Impact factor: 3.168

10.  Diabetic ketoacidosis producing extreme hyperkalemia in a patient with type 1 diabetes on hemodialysis.

Authors:  Hodaka Yamada; Shunsuke Funazaki; Masafumi Kakei; Kazuo Hara; San-E Ishikawa
Journal:  Endocrinol Diabetes Metab Case Rep       Date:  2017-09-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.